Evidence map›Paper›PMID 40491958›Full record

ArticleiScience2025

Epigenomic landscapes define differential Janus kinases inhibitor sensitivity in IFN-γ-primed human macrophages.

Geunho Kwon, Yebin Park, Keunsoo Kang, Kyung-Hyun Park-Min, Kyuho Kang

Abstract read
In one paragraph

Article in iScience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Geunho KwonDepartment of Biological Sciences and Biotechnology, Chungbuk National University, Cheongju 28644, Republic of Korea.
Yebin ParkDepartment of Biological Sciences and Biotechnology, Chungbuk National University, Cheongju 28644, Republic of Korea.
Keunsoo KangDepartment of Microbiology, College of Science & Technology, Dankook University, Cheonan 31116, Republic of Korea.
Kyung-Hyun Park-MinArthritis and Tissue Degeneration Program, David Z. Rosensweig Genomics Research Center, Hospital for Special Surgery, New York, NY 10021, USA.
Kyuho KangDepartment of Biological Sciences and Biotechnology, Chungbuk National University, Cheongju 28644, Republic of Korea.

Funding

A novel regulating pathway in osteoclastogenesis and arthritic bone resorptionR01AR073156 · NIAMS · HOSPITAL FOR SPECIAL SURGERY · PI PARK-MIN, KYUNG-HYUN · 2018 to 2022
$1.9M
Osteoclast programming and reprogramming during osteoclastogenesisR01AR083374 · NIAMS · HOSPITAL FOR SPECIAL SURGERY · PI Kyung-Hyun Park-Min · 2023 to 2026
$1.8M
NIAMS NIH HHS R01 AR073156NIAMS NIH HHS R01 AR083374
6 · The paper itself

Abstract

Janus kinases (JAK) mediate signaling pathways of multiple cytokines, including interferon-γ (IFN-γ), which plays a pivotal role in rheumatoid arthritis (RA) pathogenesis. Although JAK inhibitors (JAKi) have demonstrated efficacy for RA, their molecular effects on macrophages remain incompletely understood. We investigate the impact of JAKi on IFN-γ-induced gene expression in human macrophages, uncovering that JAKi selectively modulates only a subset of IFN-γ-induced genes. Integrated transcriptomic and epigenomic analyses demonstrate that JAKi effectively inhibits IFN-γ signature genes associated with IRF1-STAT1-dependent accessible chromatin regions. However, genes regulated by AP-1 and C/EBP remain insensitive to JAKi and overlap significantly with TNF-induced genes. Single-cell analysis of RA patient samples identifies macrophage subpopulations with variable JAKi sensitivity. Certain JAKi-insensitive genes in IFN-γ-primed macrophages are suppressed by JNK inhibitors. Our findings elucidate JAKi responsiveness mechanisms through IFN-γ-induced epigenomic remodeling, providing insights into inflammatory regulation in RA and suggesting strategies to overcome JAKi resistance.

Indexed as

Components of the immune systemImmunologyTranscriptomics

Identifiers

PMID40491958
PMCPMC12146619

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.